1-20 of 28
Ursula A. Matulonis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT008: A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer

Rebecca L. Porter, Niya Xiong, Nabihah Tayob, Madeline Polak, Hannah Sawyer, Martin Hayes, Jeanette Gardner, Susana Campos, Neil Horowitz, Carolyn Krasner, Elizabeth K. Lee, Joyce F. Liu, Elizabeth H. Stover, Jennifer Veneris, Alexi A. Wright, Ursula A. Matulonis, Panagiotis Konstantinopoulos
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2024-CT008
Published: 05 April 2024
View article titled, Abstract CT008: A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer
Journal Articles

Abstract 935: Co-clinical endometrial cancer (EC) patient-derived organoids (PDO) to assess functional effects of replication stress (RS)-targeting agents

Elena Ivanova, Aisha L. Saldanha, Shrabasti Roychoudhury, Bose Kochupurakkal, Ari P. Zlota, Clare E. Padrick, Ha V. Vo, Eli K. Greenberg, Hannah Sawyer, Carina Feeney, Courtney H. Qi, Swati Narayan, Jennifer D. Curtis, Nabihah Tayob, Marisa R. Nucci, Panagiotis Konstantinopoulos, Dipanjan Chowdhury, Geoffrey Shapiro, Cloud P. Paweletz, Ursula A. Matulonis, Joyce F. Liu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 935.
https://doi.org/10.1158/1538-7445.AM2024-935
Published: 22 March 2024
View article titled, Abstract 935: Co-clinical endometrial cancer (EC) patient-derived organoids (PDO) to assess functional effects of replication stress (RS)-targeting agents
Journal Articles

Abstract A011: An implantable microdevice to interrogate responses to therapy in ovarian cancer

Elizabeth H. Stover, Zuzana Tatarova, Sharath K. Bhagavatula, Christine Dominas, Madeline Polak, Alexis Rabbitt, Jeanette Gardner, Kim MacNeill, Natalie Azzolini, Sebastian Ahn, Michael J. Worley, Jr., Kevin M. Elias, David L. Kolin, Joyce F. Liu, Ursula A. Matulonis, Stuart G. Silverman, Neil S. Horowitz, Oliver Jonas
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): A011.
https://doi.org/10.1158/1538-7445.OVARIAN23-A011
Published: 04 March 2024
View article titled, Abstract A011: An implantable microdevice to interrogate responses to therapy in ovarian cancer
Journal Articles

Abstract 162: Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma

Brittany Meisenheimer, Ha V. Vo, Kelley E. McQueeney, Aisha L. Saldanha, Carina Feeney, Courtney H. Qi, Swati Narayan, Jennifer D. Curtis, Marisa R. Nucci, Anthony Letai, Cloud P. Paweletz, Joyce F. Liu, Ursula A. Matulonis, Elena Ivanova
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 162.
https://doi.org/10.1158/1538-7445.AM2023-162
Published: 04 April 2023
View article titled, Abstract 162: Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma
Journal Articles

Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors

Nicoletta Colombo, Toon Van Gorp, Ursula A. Matulonis, Ana Oaknin, Rachel N. Grisham, Diane Provencher, Gini F. Fleming, Alexander B. Olawaiye, Erkut H. Borazanci, Russell Z. Szmulewitz, Subhagya A. Wadekar, Grace Mann, Hazel J. Hunt, Andrew E. Greenstein, Domenica Lorusso
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3434.
https://doi.org/10.1158/1538-7445.AM2023-3434
Published: 04 April 2023
View article titled, Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors
Journal Articles

Abstract 3459: Drug persistence pathways in ovarian cancer identified by single-cell analysis of patient samples and cell line models

Elizaveta Leshchiner, Richard Panayiotou, Anay Gupta, Thomas Zhang, Kayli Neil, Nomeda Girnius, Aylin Henstridge, Brian P. Danysh, Ignaty Leshchiner, Sarah J. Hill, Laxmi Parida, Ursula A. Matulonis, Joan S. Brugge, Gad Getz
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3459.
https://doi.org/10.1158/1538-7445.AM2023-3459
Published: 04 April 2023
View article titled, Abstract 3459: Drug persistence pathways in ovarian cancer identified by single-cell analysis of patient samples and cell line models
Journal Articles

Abstract 3065: Establishment and characterization of a platform of endometrial cancer organoids

Aisha L. Saldanha, Ha V. Vo, Kevin Vasquez, Kenneth Ngo, Shrabasti Roychoudhury, Carina Feeney, Courtney H. Qi, Swati Narayan, Jennifer D. Curtis, Prafulla C. Gokhale, Dipanjan Chowdhury, Cloud P. Paweletz, Marisa R. Nucci, Ursula A. Matulonis, Elena Ivanova, Joyce F. Liu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3065.
https://doi.org/10.1158/1538-7445.AM2022-3065
Published: 15 June 2022
View article titled, Abstract 3065: Establishment and characterization of a platform of endometrial cancer organoids
Journal Articles

Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations

Kirsten Kubler, Agostina Nardone, Shankara Anand, Daniel Gorvich, Marjolein Droog, Francisco Hermida-Prado, Tara Akshi, Avery S Feit, Gabriella Cohen, Gwen Dackus, Matthew Pun, Yanan Kuang, Justin Cha, Mendy Miller, William J Gibson, Cloud P Paweletz, Eliezer M Van Allen, Flora E van Leeuwen, Petra Nederlof, Harry Hollema, Quang-Dé Nguyen, Marian JE Mourits, Ignaty Leshchiner, Chip Stewart, Ursula A Matulonis, Wilbert Zwart, Yosef E Maruvka, Gad Getz, Rinath Jeselsohn
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-09.
https://doi.org/10.1158/1538-7445.SABCS21-GS2-09
Published: 15 February 2022
View article titled, Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
Journal Articles

Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer

Felipe Batalini, Doga Gulhan, Victor Mao, Madeline Polak, Eric P. Winer, Erica L. Mayer, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos, Peter Park, Gerburg M. Wulf
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 156.
https://doi.org/10.1158/1538-7445.AM2021-156
Published: 01 July 2021
View article titled, Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer
Journal Articles

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Changxin Wan, Matthew P. Keany, Han Dong, Linah F. Al-Alem, Unnati M. Pandya, Suzan Lazo, Karsten Boehnke, Katherine N. Lynch, Rui Xu, Dominique T. Zarrella, Shengqing Gu, Paloma Cejas, Klothilda Lim, Henry W. Long, Kevin M. Elias, Neil S. Horowitz, Colleen M. Feltmate, Michael G. Muto, Michael J. Worley, Jr, Ross S. Berkowitz, Ursula A. Matulonis, Marisa R. Nucci, Christopher P. Crum, Bo R. Rueda, Myles Brown, Xiaole Shirley Liu, Sarah J. Hill
Journal: Cancer Research
Series: Author Choice
Cancer Res (2021) 81 (1): 158–173.
https://doi.org/10.1158/0008-5472.CAN-20-1674
Published: 04 January 2021
View article titled, Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Open the PDF for Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer

Joyce F. Liu, Kshama A. Doshi, Benjamin H. Lee, Marisa O. Peluso, Li Zhang, Shan Zhou, Qing Zeng, Stephen Wang, Paul T. Kirschmeier, Cam A. Tran, Cloud Paweletz, Matthew Rausch, Alison M. Paterson, Prafulla C. Gokhale, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4515.
https://doi.org/10.1158/1538-7445.AM2020-4515
Published: 15 August 2020
View article titled, Abstract 4515: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer
Journal Articles

Abstract 2615: Systematic approaches to predict oncogenic transcriptional regulatory circuitries identify important nodes in high-grade serous ovarian cancer

Brian J. Abraham, Jessica Reddy, Marcos A. Fonseca, Isaac A. Klein, Lena K. Afeyan, Rosario I. Corona, Paloma Cejas, Felipe Segato, Beth Y. Karlan, Simon A. Gayther, Matthew L. Freedman, Houtan Noushmehr, Myles Brown, Ursula A. Matulonis, Kate Lawrenson, Richard A. Young
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2615.
https://doi.org/10.1158/1538-7445.AM2019-2615
Published: 01 July 2019
View article titled, Abstract 2615: Systematic approaches to predict oncogenic transcriptional regulatory circuitries identify important nodes in high-grade serous ovarian cancer
Journal Articles

Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors

Khanh T. Do, Sarah J. Hill, Bose Kochupurakkal, Jeffrey G. Supko, Courtney Gannon, Adrienne Anderson, Alona Muzikansky, Andrew Wolanski, Jennifer Hedglin, Kalindi Parmar, Jean-Bernard Lazaro, Joyce Liu, Susana Campos, Ursula A. Matulonis, Alan D. D'Andrea, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT232.
https://doi.org/10.1158/1538-7445.AM2019-CT232
Published: 01 July 2019
View article titled, Abstract CT232: Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors
Journal Articles

Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids

Sarah J. Hill, Patrick Lizotte, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Colleen M. Feltmate, Bose Kochupurakkal, Khanh T. Do, Panagiotis Konstantinopoulos, Marisa R. Nucci, Joyce F. Liu, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 368A.
https://doi.org/10.1158/1538-7445.AM2019-368A
Published: 01 July 2019
View article titled, Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids
Journal Articles

Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer

Anniina Farkkila, Jia R. Lin, Julia Casado, Huy Nguyen, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Steven Waggoner, Pamela Munster, Gini F. Fleming, Sandro Santagata, Ursula A. Matulonis, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis Konstantinopoulos
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4487.
https://doi.org/10.1158/1538-7445.AM2019-4487
Published: 01 July 2019
View article titled, Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer
Journal Articles

Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer

Anniina Farkkila, Sameer S. Chopra, Jia-Ren Lin, Zoltan Maliga, Bose Koruchupakkal, Kyle C. Strickland, Brooke E. Howitt, Sandro Santagata, Ursula A. Matulonis, Kevin Elias, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Peter Sorger, Alan D. D'Andrea
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 139.
https://doi.org/10.1158/1538-7445.AM2018-139
Published: 01 July 2018
View article titled, Abstract 139: DNA damage and immunoprofiling with highly multiplexed tissue immunofluorescence (t-CycIF) in high-grade serous ovarian cancer
Journal Articles

Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo

Panagiotis A. Konstantinopoulos, Graeme Hodgson, Nisha Rajagopal, Liv Johannessen, Joyce F. Liu, Paul T. Kirschmeier, Shan Zhou, Cam Anh Tran, David Orlando, Christian Fritz, Emmanuelle di Tomaso, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1525.
https://doi.org/10.1158/1538-7445.AM2018-1525
Published: 01 July 2018
View article titled, Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo
Journal Articles

Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort

Panagiotis A. Konstantinopoulos, William T. Barry, Michael Birrer, Shannon N. Westin, Sarah Farooq, Karen Cadoo, Christin Whalen, Weixiu Luo, Hui Liu, Carol Aghajanian, David B. Solit, Gordon B. Mills, Barry S. Taylor, Helen Won, Michael F. Berger, Sangeetha Palakurthi, Joyce F. Liu, Lew Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D'Andrea, Eric Winer, Gerburg M. Wulf, Ursula A. Matulonis
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2017-CT008
Published: 01 July 2017
View article titled, Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Journal Articles

Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer

Ursula A. Matulonis, Alexi Wright, Susana Campos, Panagiotis Konstantinopoulos, Ariana Peralta, Kimberley MacNeill, Stephanie Morrissey, Christin Whalen, Joyce Liu
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT142.
https://doi.org/10.1158/1538-7445.AM2017-CT142
Published: 01 July 2017
View article titled, Abstract CT142: A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer
Journal Articles

Abstract 4033: Combined MEK and BCL-2/XL inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer

Claudia Iavarone, Ioannis Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ursula A. Matulonis, Ronny I. Drapkin, Gordon B. Mills, Joel D. Leverson, Deepak Sampath, Joan S. Brugge
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4033.
https://doi.org/10.1158/1538-7445.AM2017-4033
Published: 01 July 2017
View article titled, Abstract 4033: Combined MEK and BCL-2/X<sub>L</sub> inhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer